Nuvation Bio (NUVB) to Release Earnings on Monday

Nuvation Bio (NYSE:NUVB) is expected to be releasing its Q3 2025 results after the market closes on Monday, November 3rd. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $7.4830 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 3, 2025 at 4:30 PM ET.

Nuvation Bio (NYSE:NUVB) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). The business had revenue of $4.83 million during the quarter, compared to analysts’ expectations of $0.42 million. Nuvation Bio had a negative return on equity of 46.14% and a negative net margin of 1,413.43%. On average, analysts expect Nuvation Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvation Bio Trading Up 1.3%

Shares of NYSE NUVB opened at $5.22 on Friday. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -8.28 and a beta of 1.48. The business has a 50 day simple moving average of $3.63 and a 200 day simple moving average of $2.72. Nuvation Bio has a 52 week low of $1.54 and a 52 week high of $5.55. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 29.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Nuvation Bio

Several hedge funds have recently modified their holdings of the business. Millennium Management LLC boosted its position in shares of Nuvation Bio by 52.4% in the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after acquiring an additional 1,298,131 shares during the period. Marshall Wace LLP bought a new stake in shares of Nuvation Bio in the second quarter valued at approximately $1,699,000. American Century Companies Inc. boosted its position in shares of Nuvation Bio by 12.6% in the second quarter. American Century Companies Inc. now owns 547,929 shares of the company’s stock valued at $1,068,000 after acquiring an additional 61,394 shares during the period. Armistice Capital LLC bought a new stake in shares of Nuvation Bio in the second quarter valued at approximately $975,000. Finally, Invesco Ltd. boosted its position in shares of Nuvation Bio by 7.0% in the second quarter. Invesco Ltd. now owns 393,414 shares of the company’s stock valued at $767,000 after acquiring an additional 25,642 shares during the period. 61.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NUVB has been the subject of several recent research reports. Jefferies Financial Group initiated coverage on Nuvation Bio in a research note on Tuesday, September 30th. They issued a “buy” rating and a $10.00 price target for the company. Wall Street Zen raised Nuvation Bio from a “sell” rating to a “hold” rating in a research note on Sunday, August 17th. Royal Bank Of Canada boosted their price target on Nuvation Bio from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Nuvation Bio in a research note on Friday, September 19th. Finally, Wedbush reissued an “outperform” rating and issued a $6.00 price target on shares of Nuvation Bio in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.86.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.